Oligonucleotide N3'.fwdarw.P5' phosphoramidates

• US 5,965,720 A
• Filed: 01/10/1997
• Issued: 10/12/1999
• Est. Priority Date: 03/18/1994
• Status: Expired due to Term

• Current Assignee: Geron Corporation
• Original Assignee: Lynx Therapeutics, Inc. (Illumina Incorporated)
• Inventors: Schultz, Ronald G., Gryaznov, Sergei M., Chen, Jer-kang
• Primary Examiner(s): Marschel, Ardin H.
• Application Number:
  US08/700,448
• Time in Patent Office: 1,005 Days
• Field of Search: 435/6, 436/501, 536/23.1, 536/24.1, 536/24.3-24.33, 536/25.3, 514/44, 935/77, 935/78
• US Class Current: 536/23.1
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07H 19/06 Pyrimidine radicals
• CPC Class Codes: C07H 19/16 Purine radicals
• CPC Class Codes: C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

Modified oligonucleotides 3'"'"'-NHP(O)(O^-)O-5'"'"' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form more stable duplexes than phosphodiesters with complementary DNA and particularly RNA strands. Further, the phosphoramidate analogs can also form stable triplexes with double-stranded DNA target, where under similar conditions parent phosphodiester compounds failed to do so.

Claims

1. An oligodeoxyribonucleotide comprising a non-homopolymeric defined sequence of nucleoside subunits joined by intersubunit linkages wherein at least fifty percent of such intersubunit linkages are N3'"'"'→

P5'"'"' phosphoramidate linkages, and at least two of said N3'"'"'→

P5'"'"' phosphoramidate linkages are contiguous, wherein said defined sequence has a sequence complementary to mRNA from a gene selected from the group consisting of c-myc, c-myb, c-fos, c-kit, ras and BCR/ABL.

2. The oligodeoxyribonucleotide of claim 1 wherein said oligodeoxyribonucleotide includes a second linkage selected from the group consisting of phosphodiester, phosphotriester, methylphosphonate, P3'"'"'→

N5'"'"' phosphoramidate, and phosphorothioate.

3. The oligodeoxyribonucleotide of claim 2 wherein said second linkages is a phosphodiester linkage.

4. The oligodeoxyribonucleotide of claim 1, wherein the selected gene is c-myc.

5. The oligodeoxyribonucleotide of claim 4, wherein said defined sequence is selected from the group consisting of TTTCATTGTTTTCCA (SEQ ID NO:

28), AACGTTGAGGGGCAT (SEQ ID NO;

30), and UUUCAUUGUUUUCCA (SEQ ID NO;

32).

6. The oligodeoxyribonucleotide of claim 5, wherein said selected sequence is TTTCATTGTTTTCCA (SEQ ID NO:

32).

7. An oligodeoxyribonucleotide of claim 1, wherein said target sequence is characteristic of c-myb.

8. The oligodeoxyribonucleotide of claim 1 wherein said N3'"'"'→

P5'"'"' phosphoramidate linkages are defined by the formula;

space="preserve" listing-type="equation">3'"'"'-[NH--P(═

O)(--O.sup.-)--O-]-5.

9. The oligodeoxyribonucleotide of claim 8, wherein the selected gene is c-myc.

10. The oligodeoxyribonucleotide of claim 9, wherein said defined sequence is selected from the group consisting of TTTCATTGTTTTCCA (SEQ ID NO:

28), AACGTTGAGGGGCAT (SEQ ID NO;

30), and UUUCAUUGUUUUCCA (SEQ ID NO;

32).

11. The oligodeoxyribonucleotide of claim 10, wherein said selected sequence is TTTCATTGTTTTCCA (SEQ ID NO:

32).

12. An oligodeoxyribonucleotide of claim 8, wherein said target sequence is characteristic of c-myb.